Projet MAGICBULLET (Horizon 2020, appel à projets 2014)
Action : Doctoral Networks
Panel : Chemistry
Statut du projet : CLOSED

Many tumor cells are characterized by the overexpression of certain antigens. Molecules that specifically recognize these structures are suitable as homing devices in tumor therapy. Conjugates of anticancer drugs with such a delivery vector targeting tumors would be a “magic bullet” according to the Nobel laureate Paul Ehrlich. Three antibody-drug conjugates (ADC) have already been approved for anticancer therapy. However, ADC have e.g. limitations with respect to tumor penetration, high manufacturing costs, and require challenging conjugation chemistry. Peptide-drug conjugates can have a high drug loading, easily penetrate tissue, and can be easily prepared in a homogenous form with straightforward and well-defined conjugation chemistry. The ETN MAGICBULLET will focus on chemistry-driven approaches toward conjugates between peptides (delivery vectors) that recognize tumors and anticancer drugs (payloads or warheads) in order to selectively fight cancer, a topic with a high demand of research activities. The ETN will develop and validate an array of new peptide-drug conjugates combining either known tumor-specific peptides or newly discovered tumor-homing peptides with potent cytotoxic drugs. The tumor-selective peptides are designed for cellular uptake mediated either by endocytosis or by cell-penetrating peptides. The consortium of the ETN MAGICBULLET covers tumor biology, biochemistry, pharmacology, synthetic chemistry, medicinal chemistry, spectroscopy, conformational analysis, and computational chemistry. The training program focuses on multidisciplinary research to explore and validate molecular targets for innovative treatment or investigations on the molecular mechanisms in organ-specific metastatic growth processes. It aims at scientific multilingualism and relies e.g. on concerted learning, a combination of introductory training, hands-on learning “on the bench”, teaching by peers, and training in additional skills.

Mots clés : peptide drug conjugates   tumor targeting   homing device   cytotoxic drug   natural products   drug delivery

Participants :
- University of Cologne (Allemagne) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 249216.48 €
- University of Insubria (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 516122.64 €
- Exiris srl (Italie) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 258061.32 €
- IRBM Science Park (Italie) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- National Institute of Oncology (Hongrie) — Partner, beneficiary, Recherche, subvention : 223913.52 €
- Fraunhofer Society (Allemagne) — Partner, organization partner, Recherche, subvention : 0.0 €
- University of Milan (Italie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 516122.64 €
- University of Helsinki (Finlande) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 538290.72 €
- Kineto lab ltd. (Hongrie) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- University of Erlangen-Nuremberg (Allemagne) — Partner, organization partner, Enseignement supérieur ou secondaire, subvention : 0.0 €
- Eötvös Loránd University (Hongrie) — Partner, beneficiary, Enseignement supérieur ou secondaire, subvention : 447827.04 €
- Bielefeld University (Allemagne) — Coordinator, beneficiary, Enseignement supérieur ou secondaire, subvention : 498432.96 €
- Bayer (Germany) (Allemagne) — Partner, organization partner, Organismes privés (hors enseignement), subvention : 0.0 €
- Heidelberg Pharma (Germany) (Allemagne) — Partner, beneficiary, Organismes privés (hors enseignement), subvention : 498432.96 €